Healthcare Technology Report September 11, 2024

Merck, known as MSD outside the US and Canada, has announced a definitive agreement to acquire CN201, a promising bispecific antibody developed by Curon Biopharmaceutical. This transaction, valued at $700 million upfront, includes potential milestone payments up to $600 million. CN201, currently in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Building Resilience: CDMO Strategies for Drug Supply Chain Stability
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s
STAT+: How Trump’s tariffs may raise health care costs, from medical devices to prescription drugs
One Institution’s Evidence-Based Approach to Adopting Biosimilars
Cell and Gene Therapies — Improving Access and Outcomes for Medicare and Medicaid Beneficiaries

Share This Article